PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate lipid and glucose metabolism and cellular differentiation. PPAR-alpha and PPAR-gamma are both expressed in human macrophages where they exert anti-inflammatory effects. The activation of PPAR-alpha may promote foam-cell formation by inducing expression of the macrophage scavenger receptor CD36. This prompted us to investigate the influence of different PPAR-activators on cholesterol metabolism and foam-cell formation of human primary and THP-1 macrophages. Here we show that PPAR-alpha and PPAR-gamma activators do not influence acetylated low density lipoprotein-induced foam-cell formation of human macrophages. In contrast, PPAR-alpha and PPAR-gamma activators induce the expression of the gene encoding ABCA1, a transporter that controls apoAI-mediated cholesterol efflux from macrophages. These effects are likely due to enhanced expression of liver-x-receptor alpha, an oxysterol-activated nuclear receptor which induces ABCA1-promoter transcription. Moreover, PPAR-alpha and PPAR-gamma activators increase apoAI-induced cholesterol efflux from normal macrophages. In contrast, PPAR-alpha or PPAR-gamma activation does not influence cholesterol efflux from macrophages isolated from patients with Tangier disease, which is due to a genetic defect in ABCA1. Here we identify a regulatory role for PPAR-alpha and PPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This mechanism is pivotal in controlling intracellular lipid content and serves as a primary “gatekeeper” for reverse cholesterol transport in cells [23].”
From miR-223 accelerates lipid droplets clearance in microglia following spinal cord injury by upregulating ABCA1 (2024) · cites this paper as [23]
In the citing paper
“The activation of PPARα also accelerates reverse cholesterol transport (RCT) via increased expression of ABCA1 and ABCG1 transporters involved in cholesterol efflux from macrophages [29, 40].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [40]
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630 · cited 1×
“, and this led to the suggestion that PPAR-activators may modulate foam-cell formation, a known atherogenic process characterized by cholesteryl-ester-droplet accumulation in the cytoplasm of macrophage”
BackgroundThe peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899 · cited 1×
“Both PPAR-α and PPAR-γ are expressed in fully-differentiated human macrophages where they regulate genes implicated in the inflammatory response, modulate macrophage differentiation and promote TNF-α/IFN-γ–induced apoptosi”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“We treated these cells with either the PPAR-α ligand Wy14643 or the PPAR-γ ligand rosiglitazone at concentrations of 2–3 times their EC 50 values (Wy14643 EC 50 for human PPAR-αe25 μM and rosiglitazone EC 50 for human PPAR-γe43 nM”
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 1×
“Moreover, PPAR-α activation results in the transcriptional induction of CD36 expression in macrophage”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 1×
“The stimulatory role of PPAR-α activators on hepatic HDL production and apoAI expression is well-documente”
BackgroundSelf-citationMutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
An oxysterol signalling pathway mediated by the nuclear receptor LXRα
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., & Mangelsdorf, D. J. (1996) · Nature · doi:10.1038/383728a0 · Cited by 1,591 · cited 1×
“We also show that both PPAR-α and PPAR-γ activators induce ABCA1 expression, possibly through their inductive effects on expression of LXR-α, a nuclear receptor activated by oxysterol”
Background
Cited by
Items 901–1,000 of 1,000
Nakamura, T., Saito, Y., Ohyama, Y., Uchiyama, T., Sumino, H., & Kurabayashi, M. (2004) · Hypertension Research · doi:10.1291/hypres.27.589 · Cited by 7
PARK, S. E., Kang, E. S., Kim, D. H., Kim, S. K., Lee, J. H., Ahn, C. W., Lee, H. C., & Cha, B. S. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02728.x · Cited by 7
BENGTSSON, S. H. M., Madeyski-Bengtson, K., Nilsson, J., & Bjursell, G. (2002) · Biochemical Journal · doi:10.1042/bj20020223 · Cited by 7
Nuclear transcription factors and lipid homeostasis in liver
Chen, Y., Huang, A., & Ruan, X. Z. (2007) · Chinese Medical Journal · doi:10.1097/00029330-200712020-00026 · Cited by 7
ABCA1 Single Nucleotide Polymorphisms
Dong, C., Nevins, J. R., & Goldschmidt‐Clermont, P. J. (2001) · Circulation Research · doi:10.1161/hh0901.091208 · Cited by 7
Yue, Y., Zou, D., Tian, S., Jiao, H., & Zhao, H. (2024) · Journal of Systematics and Evolution · doi:10.1111/jse.13060 · Cited by 7
“This protein plays a pivotal role not only in the formation of nascent high ‐ density lipoprotein but also in the regulation of intracellular cholesterol e ffl ux after activation of PPARs (Chinetti et al., 2001).”
Gargareta, V., Berghoff, S. A., Krauter, D., Hümmert, S., Marshall-Phelps, K. L., Möbius, W., Nave, K., Fledrich, R., Werner, H. B., & Eichel‐Vogel, M. A. (2024) · Glia · doi:10.1002/glia.24568 · Cited by 6
Sharma, D., Patel, D. N., & Mandal, P. (2025) · Mediators of Inflammation · doi:10.1155/mi/9948679 · Cited by 6
Srivastava, N., Cefalu, A. B., Averna, M. R., & Srivastava, R. A. K. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00517-0 · Cited by 8
FNDC5 Attenuates Atherosclerotic Plaque Formation and Regulates PPARα/HO-1 in ApoE−/− Mice
Zhou, B., Wang, X., Wang, Y., & Liu, D. (2023) · Journal of Vascular Research · doi:10.1159/000531585 · Cited by 6
Yan, C., Wang, L., Liu, Y., Ma, Y., Wang, R., Han, X., Qiao, H., Lin, J., Matsuura, E., Liu, S., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.01.052 · Cited by 6
Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice
den Boer, M. A. M., Westerterp, M., der Weij, J. D. V.-V., Wang, Y., Hu, L., Santo, S. M. S. E., Kooistra, T., Reiss, P., Romijn, J. A., Havekes, L. M., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.11.043 · Cited by 6
Batra, S. D., Nandi, M., Sikri, K., & Tyagi, J. S. (2017) · BMC Genomics · doi:10.1186/s12864-017-3635-4 · Cited by 7
Dou, F., Wu, B., Sun, L., Chen, J., Liu, T., Yu, Z., & Chen, C. (2019) · Open Biology · doi:10.1098/rsob.190141 · Cited by 6
Expression of ABC transporter and scavenger receptor mRNAs in PBMCs in 100‐km ultramarathon runners
Juan, C., Li, L., Hou, S., Liu, P., Kao, W., Chiu, Y., & How, C. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13365 · Cited by 6
Gangwal, R. P., Damre, M. V., Das, N. R., Sharma, S. S., & Sangamwar, A. T. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.11.052 · Cited by 6
The Role of IL-10 in Atherosclerosis
Han, X., & William, A. (2012) · InTech eBooks · doi:10.5772/25383 · Cited by 6
Guri, A. J., Hontecillas, R., & Bassaganya-Riera, J. (2008) · Lifestyle Genomics · doi:10.1159/000112460 · Cited by 6
Jones, P. H. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50030-5 · Cited by 6
Demer, L. L. (2002) · Circulation Research · doi:10.1161/res.90.3.241 · Cited by 6
Liu, K., Li, G., Liang, X., Wang, C., Zhu, N., Fu, X., Zhang, Y., Liu, C., & Yang, J. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.12.036 · Cited by 9
“PPAR-γ regulates glucose and lipid metabolism by initiating gene transcription and protein expression, thereby suppressing inflammation, vascular smooth muscle proliferation, and foam cell formation while stabilizing atheromatous plaques [48].”
Chen, Y.-C., Chen, J.-H., Tsai, C., Wu, C.-T., Chang, P.-C., & Yeh, W. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116818 · Cited by 8
Research progress on the role of macrophages in acne and regulation by natural plant products
Zhao, D., Wang, Y., Wu, S., Ji, X., Gong, K. Q., Zheng, H., & Zhu, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383263 · Cited by 10
Gang, J., Yan, F., Xu, Y., Li, J., Feng, W., Hua, G., Li, W., Zhou, J., & Tang, Y. (2024) · Aquaculture Reports · doi:10.1016/j.aqrep.2024.102607 · Cited by 7
Pulmonary surfactant in asthma
Blanco, O., Díaz-Reyes, M., Labrada, A., Autilio, C., & Pérez‐Gil, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178064 · Cited by 5
Binding Model of Amentoflavone to Peroxisome Proliferator-Activated Receptor γ
Lee, J., Kim, J., Lee, S.-J., Lee, E., Shin, S., Jin, Q., Yoon, D., Woo, E., & Kim, Y. (2012) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2012.33.5.1475 · Cited by 5
Singh, B., Sangle, G. V., Murugan, J., Umrani, R. D., Roy, S., Kulkarni, O. P., Semwal, A., Unnikrishnan, M. K., & Jain, M. R. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-45 · Cited by 5
He, L., Zhou, X., Liu, J., Yao, Y., Lin, J., Chen, J., Qiu, S., Liu, Z., He, Y., Yi, Y., et al. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.115513 · Cited by 7
Harrer, D. C., Lüke, F., Pukrop, T., Ghibelli, L., Gerner, C., Reichle, A., & Heudobler, D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1289222 · Cited by 5
El monocito/macrófago como diana terapéutica en la aterosclerosis
Pou, J., Rebollo, A., & Alegret, M. (2007) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(07)74180-3 · Cited by 6
Ppar-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis
Fruchart, J., Staels, B., & Duriez, P. (2003) · Progress in experimental cardiology · doi:10.1007/978-1-4419-9232-1_1 · Cited by 5
Self-citationTranscriptional regulation of the human Liver X Receptor α gene by Hepatocyte Nuclear Factor 4α
Theofilatos, D., Anestis, A., Hashimoto, K., & Kardassis, D. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.12.031 · Cited by 6
Chinetti, G., Copin, C., Derudas, B., Marx, N., Eeckhoute, J., & Staels, B. (2016) · PPAR Research · doi:10.1155/2016/2756781 · Cited by 6
Self-citationAlleviation of Toxicity Caused by Overactivation of Pparα through Pparα-Inducible miR-181a2
Cheng, Y., Wei, Z., Xie, S., Peng, Y., Yan, Y., Qin, D., Liu, S., Xu, Y., Li, G., & Zhang, L. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.09.008 · Cited by 4
Tsimikas, S. (2006) · Developments in cardiovascular medicine · doi:10.1007/0-387-29553-4_2 · Cited by 5
Fuster, V., & Sanz, J. (2007) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2006.11.005 · Cited by 6
Grzych, G., Bernard, L., Lestrelin, R., Tailleux, A., & Staels, B. (2022) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2022.09.005 · Cited by 6
Self-citationBIGKnock: fine-mapping gene-based associations via knockoff analysis of biobank-scale data
Ma, S., Wang, C., Khan, A., Liu, L., Dalgleish, J. L. T., Kiryluk, K., He, Z., & Ionita‐Laza, I. (2023) · Genome biology · doi:10.1186/s13059-023-02864-6 · Cited by 5
Identification of collaboration patterns of dysfunctional pathways in breast cancer.
Zhu, X., Tao, L., Yao, J., Sun, P., Pei, L., Li, J., Long, Z., Wang, Y., & Zhang, F. (2014) · PubMed Central · Cited by 5
An evaluation of the mechanism of ABCA7 on cellular lipid release in ABCA7-HEC293 cell
Chengai, W., Wang, N., & Dan-hui, Z. H. A. O. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20123502 · Cited by 6
Genetics of the metabolic syndrome and implications for therapy
Hughes, R. I., & Aitman, T. J. (2004) · International Congress Series · doi:10.1016/j.ics.2003.12.005 · Cited by 6
Zahradka, P. C. (2007) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2007.00008.x · Cited by 7
Lai, Y.-C., Li, H., Wu, T.-J., Jeng, C.-Y., & Chuang, L. (2014) · PPAR Research · doi:10.1155/2014/917823 · Cited by 5
“Activation of PPAR𝛾 influences cholesterol metabolism by enhancing the reverse cholesterol transport pathway through the efflux of cholesterol to lipid-poor apolipoprotein A-I [7].”
BackgroundInfluentialAhmed, S. H., Kharroubi, W., Zarrouk, A., Brahmi, F., Nury, T., Lizard, G., & Hammami, M. (2016) · Current Research in Translational Medicine · doi:10.1016/j.retram.2016.08.001 · Cited by 7
Blaschke, F., Bruemmer, D., & Law, R. E. (2004) · Clinical Cardiology · doi:10.1002/clc.4960271603 · Cited by 6
Ziaee, S. M., Nemati, S. H., Kataria, H., Jakova, E., Hosseini, S. M., Ghelich, P., McLeod, G. A., Tamayol, A., Yong, V. W., & Karimi‐Abdolrezaee, S. (2026) · Nature Communications · doi:10.1038/s41467-026-72639-7 · Cited by 4
Higashi, N., Matsumura, Y., Mizuno, F., Kasahara, K., Sugiura, S., Mikasa, K., & Kita, E. (2010) · Microbial Pathogenesis · doi:10.1016/j.micpath.2010.05.005 · Cited by 4
Benzotriazole ultraviolet stabilizer UV-234 promotes foam cell formation in RAW264.7 macrophages
Shen, X., Hu, W., Xu, C., Xu, C., Wan, Y., & Hu, J. (2022) · Environmental Pollution · doi:10.1016/j.envpol.2022.120560 · Cited by 6
Lin, S., Hou, L., Wang, Y., Lin, H., Deng, J., Li, S., Long, H., & Zhao, G. (2024) · Gene · doi:10.1016/j.gene.2024.148302 · Cited by 4
p-Coumaric acid modulates cholesterol efflux and lipid accumulation and inflammation in foam cells
Moon, H.-R., & Yun, J. (2024) · Nutrition Research and Practice · doi:10.4162/nrp.2024.18.6.774 · Cited by 5
Mechanistic Insights into N-Oleoylethanolamide-Mediated Hepatoprotection via PPAR-α
Ivashkevich, D., Ponomarenko, A., Manzhulo, I., & Dyuizen, I. (2025) · Biocell · doi:10.32604/biocell.2025.061606 · Cited by 5
“Fibrate, a traditional PPAR-α activator, affects the expression of many genes, which reduces macrophage activation [106], inhibits the growth of vascular smooth muscle cells [107], and speeds up the macrophages’ clearance of lipids [108].”
Feng, H., Jiang, K., Zhang, Y., Zhuang, J., Ku, C., Yang, J., & Zhang, Y. (2025) · Journal of Nutrition and Metabolism · doi:10.1155/jnme/1827252 · Cited by 4
“In addition, research has shown that the PPAR gene is associated with TC, LDL-C, and some infammatory markers [54], and the activation of PPAR-α and PPAR-γ facilitates cholesterol clearance [55].”
Matsumura, T., Taketa, K., Shimoda, S., & Araki, E. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00182.x · Cited by 4
Cardiometabolic interventions – focus on transcriptional regulators
Chai, J. T., & Choudhury, R. P. (2013) · European Journal of Cardiovascular Medicine · doi:10.5083/ejcm.20424884.102 · Cited by 4
Development of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities
Pinaire, J. A., Miller, A. R., & Gregoire, F. M. (2008) · PPAR Research · doi:10.1155/2008/786359 · Cited by 4
“Many aspects of TZD-induced fluid retention have been covered by excellent review articles [6–12].”
BackgroundInfluentialPPARs: Important Regulators in Metabolism and Inflammation
Sanderson, L. M., & Kersten, S. (2010) · Springer eBooks · doi:10.1007/978-90-481-3303-1_10 · Cited by 7
“In addition, macrophage PPARγ governs cholesterol esterification and intracellular cholesterol distribution, and stimulates cholesterol removal from the macrophage via the target genes ABCA1, ABCG1, caveolin and APOE1 [34, 215–219].”
BackgroundBurgess, J. W., Sinclair, P. A., Chretien, C. M., Boucher, J., & Sparks, D. L. (2006) · Springer eBooks · doi:10.1007/0-387-36279-3_1 · Cited by 4
“These factors allow regulation through many diverse metabolites, including cAMP [5], sterols [22], cis-retinoic acid [23], PPAR agonists [24], and interferon-γ [25].”
BackgroundThe Legacy of Infectious Disease Exposure on the Genomic Diversity of Indigenous Southern Mexicans
Garcia, O. A., Arslanian, K. J., Whorf, D., Thariath, S., Shriver, M. D., Li, J. Z., & Bigham, A. W. (2023) · Genome Biology and Evolution · doi:10.1093/gbe/evad015 · Cited by 3
Yamada, H., Uemura, A., & Miyasaka, R. (2023) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbad025 · Cited by 4
Huang, C., Yu, X., Shi, C., Wang, M., Li, A., & Wang, F. (2023) · British Journal Of Nutrition · doi:10.1017/s0007114523002970 · Cited by 4
“When AMPK is phosphorylated by upstream kinases (52) , it transduces a signal sensed by PPAR α (53) and finally regulates serum levels of HDL-cholesterol (54) .”
InfluentialMyeloid Cell Diversity and Impact of Metabolic Cues during Atherosclerosis
Gallerand, A., Stunault, M. I., Merlin, J., Guinamard, R., Yvan‐Charvet, L., & Ivanov, S. (2020) · Immunometabolism · doi:10.20900/immunometab20200028 · Cited by 8
Kortesoja, M., Taavitsainen-Wahlroos, E., & Hanski, L. L. (2021) · Advances in Redox Research · doi:10.1016/j.arres.2021.100001 · Cited by 4
Transcription Factors That Regulate Macrophage Development and Function
Hume, D. A., & Himes, S. R. (2003) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-55742-2_2 · Cited by 7
Effects of thiazolidinediones on cardiovascular risk factors
Gouda, B. P., Asnani, S., & Fonseca, V. A. (2002) · Comprehensive Therapy · doi:10.1007/s12019-002-0018-8 · Cited by 4
Glitazones in the treatment of cardiovascular risk factors
Bouhlel, M. A., Chinetti, G., & Staels, B. (2007) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00531.x · Cited by 6
Self-citationAtta, M. L. B. S., Crook, D., Shafique, F., Johnston, D. G., & Godsland, I. F. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-04-0213 · Cited by 4
Ma, T., Ma, Z., Du, X., Yu, Q.-S., Wang, R., & Liu, L. (2015) · PubMed Central · Cited by 4
Hepatic aberrant glycosylation byN-acetylglucosaminyltransferase V accelerates HDL assembly
Kamada, Y., Kida, S., Hirano, K., Yamaguchi, S., Suzuki, A., Hashimoto, C., Kimura, A., Sato, M., Fujii, H., Sobajima, T., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00231.2016 · Cited by 4
Nuclear Receptors and the Adaptive Response of the Heart
Parry, T. L., Ledee, D. R., Willis, M. S., & Portman, M. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803111-7.00010-5 · Cited by 6
[A case of herpes zoster myelitis improved with acyclovir].
Yasuda, Y., Akiguchi, I., & Kameyama, M. (1990) · PubMed · Cited by 4
Fundamentals of Human Nutrition
Heber, D., & Bowerman, S. (2006) · Elsevier eBooks · doi:10.1016/b978-012088393-6/50057-9 · Cited by 4
Peroxisome Proliferator–Activated Receptors and The Metabolic Syndrome
Meiliana, A., & Wijaya, A. (2009) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v1i1.79 · Cited by 8
Cohen, R. A. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000137187.16206.79 · Cited by 5
Pharmacological and Toxicological Advances in PPAR-Related Medicines
Kamijo, Y., Nicol, C. J. B., & Alexson, S. E. H. (2012) · PPAR Research · doi:10.1155/2012/940964 · Cited by 4
Valledor, A. F., Lloberas, J., & Celada, A. (2015) · Wiley eBooks · doi:10.1002/9780470015902.a0020730.pub2 · Cited by 7
Fruchart, J., Staels, B., & Duriez, P. (2001) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)34590-x · Cited by 4
Self-citationReal-time RT-PCR v1Preprint
Wang, Y. J. (2017) · doi:10.17504/protocols.io.iencbde · Cited by 4
Zhao, S., Song, Y., Nakashima, Y., Zou, X., Koga, T., Ishida, T., Li, R., Hirota, Y., Tanaka, Y., & Ishii, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073363 · Cited by 4
“A previous study showed that PPARG activators induce ABCA1 expression and cholesterol removal from macrophages [51].”
Yang, X.-F., Hao, Z.-M., Cui, X., Liu, W.-Q., Li, M., & Shang, D. (2025) · Cells · doi:10.3390/cells14181470 · Cited by 3
“The activation of PPAR γ upregulates ABCA1 and ABCG1 expression, thereby promoting cellular cholesterol efflux [41].”
N-Stearoylethanolamine Exerts Cardioprotective Effects in Old Rats
Kosiakova, H. V., Ah, B., Tm, H., Meged’, O. F., Klimashevsky, V., Matsokha, R., Tkachenko, O. S., Vs, A., Kvitnitskaya-Ryzhova, T., Lugovskyi, S. P., et al. (2024) · Current Aging Science · doi:10.2174/0118746098275323231226073348 · Cited by 4
Kudinov, V. A., Zakharova, T. S., Torkhovskaya, T. I., Ipatova, O. M., & Archakov, A. I. (2018) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750818020075 · Cited by 3
Pineda‐Torra, I., Fruchart, J., & Staels, B. (2000) · Springer eBooks · doi:10.1007/978-4-431-68424-4_21 · Cited by 3
Self-citationMeasuring Biomarkers to Assess the Therapeutic Effects of Ppar Agonists?
Chinetti, G., & Staels, B. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.11.1567 · Cited by 4
Self-citationCETP antagonism versus agonism in cardiovascular prevention and plaque regression
Sirtori, C. R., & Mombelli, G. G. (2009) · Clinical Lipidology · doi:10.2217/17584299.4.1.63 · Cited by 3
Ayaori, M., Kusuhara, M., & Ohsuzu, F. (2006) · Future Lipidology · doi:10.2217/17460875.1.4.477 · Cited by 3
Rashid, I., Brown, B. E., van Reyk, D. M., & Davies, M. J. (2006) · Springer eBooks · doi:10.1007/0-387-36279-3_12 · Cited by 5
Vogel, H. G. (2007) · Springer eBooks · doi:10.1007/978-3-540-70995-4_14 · Cited by 4
Wittmann, A., Bartels, A., Alkotub, B., Bauer, L., Kafshgari, M. H., & Multhoff, G. (2023) · Strahlentherapie und Onkologie (Print) · doi:10.1007/s00066-023-02130-5 · Cited by 4
“The removal of cholesterol from foam cells is regulated by the transcription factor peroxisome proliferator-activated receptor alpha and gamma (PPAR-α , PPAR-γ ), which inhibits lipid-me-tabolizing enzymes [30, 31].”
BackgroundPPARs, RXRs, and Drug‐Metabolizing Enzymes
Hardwick, J. P., & Chiang, J. Y. L. (2009) · PPAR Research · doi:10.1155/2009/589626 · Cited by 4
Thompson, J. E. S. (2014) · Figshare · doi:10.25401/cardiffmet.20319141 · Cited by 6
Targeting the colony-stimulating factor 1 axis for the treatment of Tenosynovial Giant Cell Tumors
Humbert, P., Vialle, C., Chevalerias, M., Crenn, V., Waast, D., Boutet, M., Blanchard, F., & Goff, B. L. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.10.007 · Cited by 2
Molecular Basis of Lipoprotein Disorders, Atherogenesis, and Thrombosis
Marín-García, J. (2007) · Elsevier eBooks · doi:10.1016/b978-012373698-7/50008-5 · Cited by 5
Mosaad, M. N., Awaad, M. H., El-hodairy, F. E.-H., El-Zayat, S. R., Ibrahim, S., Salama, S. F., & El-Azma, M. H. (2014) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 2
Tan, M. H. (2003) · Revista Clínica Española · doi:10.1016/s0014-2565(03)71190-4 · Cited by 2
Nakaya, N., & Goto, Y. (2003) · Current Therapeutic Research · doi:10.1016/j.curtheres.2003.09.011 · Cited by 2
Gene-Activators Prevent and Regress Atherosclerosis and Reduce Mortality
Luoma, P. V. (2009) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152509789541918 · Cited by 2
Kim, J., Shin, S., Lee, J., Lee, S., Lee, E., Jin, Q., Lee, J., Woo, E., Lee, D., Yoon, D., et al. (2011) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2011.32.8.2717 · Cited by 2
The Effect of PPARs on Coronary Heart Disease
Kuo, C. T., Tasy, P.-Y., & Tang, C.-C. (2007) · Zhōnghuá mínguó xīnzàngxué huì zázhì · Cited by 2
Receptores activados por proliferadores peroxisómicos y aterosclerosis
Carrera, M. V. (2002) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(02)78879-7 · Cited by 2
Tham, D. M., Zhang, L., Martin-McNulty, B., Wang, Y. X., Sullivan, M., & Rutledge, J. C. (2005) · Journal of Applied Research · Cited by 2
Metadata
- Authors
- Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H. B., Fruchart, J.-C., Clavey, V., & Staels, B.
- Affiliations
- Inserm (FR)
- National Institutes of Health (US)
- Sanofi (France) (FR)
- Corresponding author
- Staels, Bart
- Venue
- Nature Medicine
- Published
- 2001-01
- Volume
- 7
- Issue
- 1
- Pages
- 53-58
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1524478189
- Cited by
- 1,170
- References
- 39
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 31 · 2023: 41 · 2022: 25 · 2021: 28 · 2020: 30 · 2019: 20 · 2018: 29 · 2017: 31 · 2016: 38 · 2015: 33 · 2014: 50 · 2013: 37 · 2012: 38
- FWCI
- 99.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PPARα, PPARγ, ABCA1, cholesterol efflux, foam cells, macrophages, reverse cholesterol transport, liver X receptor alpha, apolipoprotein A-I, Tangier disease, acetylated LDL, CD36, THP-1 macrophages
- MeSH terms
- Base Sequence, Biological Transport, Cells, Cultured, Cholesterol, Foam Cells, Humans, Transcription Factors, DNA Primers, Receptors, Cytoplasmic and Nuclear, ATP-Binding Cassette Transporters, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.